Jounce Therapeutics is dedicated to transforming the treatment of cancer.Jounce Therapeutics is a clinical stage immuno-oncology company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce integrates translational science insights, including identification of related biomarkers designed to match the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more long-lasting responses to treatment.
Recent Press Releases
06/05/17Jounce Therapeutics Presents Phase 1 Data from ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors...
05/17/17Jounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical On...
View More Releases
NASDAQ GS JNCE (Common Stock)
$13.58 + 0.18 (1.34%)
Data provided by NASDAQ. Stock information is delayed a minimum of 15 minutes.
07/21/17 2:15 p.m. ET
View More Events